Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) EBITDA (2024 - 2025)

Historic EBITDA for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$16.3 million.

  • Xilio Therapeutics' EBITDA fell 1616.98% to -$16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.5 million, marking a year-over-year change of. This contributed to the annual value of -$58.2 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Xilio Therapeutics' EBITDA stood at -$16.3 million, which was down 1616.98% from -$15.8 million recorded in Q2 2025.
  • Over the past 5 years, Xilio Therapeutics' EBITDA peaked at -$13.1 million during Q4 2024, and registered a low of -$16.3 million during Q3 2025.